Efficacy and safety of a new human fibrinogen concentrate in patients with congenital fibrinogen deficiency: an interim analysis of a Phase III trial

Publisher： John Wiley & Sons Inc

E-ISSN： 1537-2995|58|2|413-422

ISSN： 0041-1132

Source： TRANSFUSION, Vol.58, Iss.2, 2018-02, pp. : 413-422

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacokinetics, clot strength and safety of a new fibrinogen concentrate: randomized comparison with active control in congenital fibrinogen deficiency

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 16, Iss. 2, 2018-02 ,pp. : 253-261

John Wiley & Sons Inc

Access to resources Recommend Favorite

Postauthorization safety study of Clottafact®, a triply secured fibrinogen concentrate in acquired fibrinogen deficiency: a prospective observational study

By  

VOX SANGUINIS, Vol. 113, Iss. 2, 2018-02 ,pp. : 120-127

John Wiley & Sons Inc

Access to resources Recommend Favorite

Use of fibrinogen concentrate in bleeding patients

By  

ANAESTHESIA, Vol. 3-2409, Iss. 11, 2015-11 ,pp. : 1323-1324

John Wiley & Sons Inc

Access to resources Recommend Favorite

Use of fibrinogen concentrate in bleeding patients

By  

ANAESTHESIA, Vol. 70, Iss. 11, 2015-11 ,pp. : 1323-1324

John Wiley & Sons Inc

Access to resources Recommend Favorite

Final Safety and Efficacy Analysis of a Phase I/II Trial with Imatinib and Vinorelbine for Patients with Metastatic Breast Cancer

By  

Oncology, Vol. 87, Iss. 5, 2014-08 ,pp. : 300-310

Karger

Access to resources Recommend Favorite